Cyclerion Therapeutics, Inc. (CYCN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

21.69 k

Shareholding (Mar 2025)

FII

4.86%

Held by 5 FIIs

DII

79.79%

Held by 7 DIIs

Promoter

8.63%

What does Cyclerion Therapeutics, Inc. do?

22-Jun-2025

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious and orphan diseases. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $9.97 million.

Who are in the management team of Cyclerion Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Cyclerion Therapeutics, Inc. includes Ms. Marsha Fanucci (Independent Chairman) and Dr. Peter Hecht (CEO), along with independent directors Mr. Kevin Churchwell, Mr. George Conrades, Dr. Ole Isacson, Ms. Stephanie Lovell, and Mr. Terrance McGuire. They are responsible for the company's strategic direction and governance.

Is Cyclerion Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Cyclerion Therapeutics, Inc. to determine a bullish or bearish outlook.

Is Cyclerion Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, Cyclerion Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, outperforming peers and the Sensex.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -14.10% and Operating profit at 14.39% over the last 5 years

The company has declared Positive results for the last 8 consecutive quarters

Risky - Negative EBITDA

High Institutional Holdings at 41.35%

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.35

Return on Equity

-42.31%

Price to Book

0.88

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-29.9%

6 Months

-46.96%

1 Year

5.59%

2 Years

-31.63%

3 Years

94.0%

4 Years

-95.2%

5 Years

-44.81%

Cyclerion Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Cyclerion Therapeutics, Inc. Announces Revision in Its Stock Evaluation Amid Financial Trends

Cyclerion Therapeutics, Inc. reported flat financial performance for the quarter ending June 2025, highlighting both strengths and challenges. Key metrics included a peak operating cash flow and net profit for the half-year, but the company also faced high debt levels and significant operating losses amid market volatility.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-14.10%

EBIT Growth (5y)

14.39%

EBIT to Interest (avg)

-35.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.41

Sales to Capital Employed (avg)

0.16

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

41.35%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.16

EV to EBIT

-1.89

EV to EBITDA

-1.89

EV to Capital Employed

1.28

EV to Sales

3.16

PEG Ratio

Dividend Yield

ROCE (Latest)

-67.44%

ROE (Latest)

-37.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (6.72%)

Foreign Institutions

Held by 5 Foreign Institutions (4.86%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -94.44% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 78.57% vs -380.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-1.50",
          "chgp": "-13.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-1.40",
          "chgp": "78.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,978.50%",
          "val2": "-17,987.70%",
          "chgp": "0.92%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 75.40% vs 30.77% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-9.60",
          "chgp": "62.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-3.30",
          "chgp": "112.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-12.60",
          "chgp": "75.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,814.00%",
          "val2": "0.00%",
          "chgp": "-181.40%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.10

Operating Profit (PBDIT) excl Other Income

-1.70

-1.50

-13.33%

Interest

0.00

Exceptional Items

1.30

0.00

Consolidate Net Profit

-0.30

-1.40

78.57%

Operating Profit Margin (Excl OI)

-17,978.50%

-17,987.70%

0.92%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -94.44% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 78.57% vs -380.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.00

0.00

Operating Profit (PBDIT) excl Other Income

-3.60

-9.60

62.50%

Interest

0.00

Exceptional Items

0.40

-3.30

112.12%

Consolidate Net Profit

-3.10

-12.60

75.40%

Operating Profit Margin (Excl OI)

-1,814.00%

0.00%

-181.40%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 75.40% vs 30.77% in Dec 2023

All Annual Results

Company CV

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.

Company Coordinates

Company Details

155 Federal Street, Suite 700 , BOSTON MA : 02110-1727

Tel: 1 617 6217722

https://www.cyclerion.com/

Registrar Details

Cyclerion Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Cyclerion Therapeutics, Inc. do?

Watch in Real-Time

Who are in the management team of Cyclerion Therapeutics, Inc.?

Is Cyclerion Therapeutics, Inc. technically bullish or bearish?

Is Cyclerion Therapeutics, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -14.10% and Operating profit at 14.39% over the last 5 years

The company has declared Positive results for the last 8 consecutive quarters

Risky - Negative EBITDA

High Institutional Holdings at 41.35%

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Cyclerion Therapeutics, Inc. Announces Revision in Its Stock Evaluation Amid Financial Trends

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Cyclerion Therapeutics, Inc.

Company Coordinates